Application of KNCN protein in tuberculosis diagnostic reagents

By capturing tuberculosis antigens using recombinant KNCN protein, the problem of insufficient sensitivity and specificity in existing tuberculosis diagnostic methods has been solved, achieving efficient and low-cost tuberculosis detection, and applicable to the specific capture and diagnosis of multiple tuberculosis antigens.

CN117486995BActive Publication Date: 2026-11-10BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311456625.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-03
Publication Date
2026-11-10
Estimated Expiration
2043-11-03

AI Technical Summary

Technical Problem

Existing tuberculosis diagnostic methods suffer from problems such as long testing time, high cost, and insufficient sensitivity and specificity. In particular, the diagnosis of multidrug-resistant tuberculosis is difficult, and there is a lack of efficient and low-cost detection technologies.

Method used

By utilizing recombinant KNCN protein to capture tuberculosis antigen, purifying KNCN protein through recombinant plasmid expression, and combining mass spectrometry and enzyme-linked reaction to detect tuberculosis antigen in patient samples, a highly sensitive and specific detection method was developed.

Benefits of technology

It improves the sensitivity and specificity of tuberculosis detection, reduces testing costs, simplifies the diagnostic process, is applicable to the specific capture of multiple tuberculosis antigens, and is suitable for patients with different immune statuses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004530714990000071
    Figure BDA0004530714990000071
Patent Text Reader

Abstract

This invention belongs to the field of tuberculosis diagnosis, specifically relating to the application of a recombinant KNCN protein in tuberculosis diagnosis. The recombinant KNCN protein has the characteristic of specifically and efficiently capturing multiple tuberculosis antigens. This invention utilizes the ability of KNCN protein to simultaneously capture several or more than a dozen tuberculosis antigens in tuberculosis patient specimens. The recombinant KNCN protein is expressed and purified to detect its ability to capture and bind antigens.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of tuberculosis diagnosis, specifically relating to the application of a KNCN protein in a tuberculosis diagnostic reagent. Background Technology

[0002] Tuberculosis (TB) is a chronic infectious disease caused by the intracellular bacterial pathogen Mycobacterium tuberculosis. Due to the unique pathogenic characteristics and transmission patterns of Mycobacterium tuberculosis, especially the emergence of drug-resistant Mycobacterium tuberculosis and cross-infection with human immunodeficiency virus (HIV) in recent years, the prevalence of TB has shown a resurgence. Mycobacterium tuberculosis is an intracellular infectious bacterium and one of the most successful pathogens, having evolved various strategies to adapt to host cells and evade immune surveillance. After entering the human body through the respiratory tract, Mycobacterium tuberculosis mainly parasitizes macrophages, employing multiple strategies to evade the host cell's immune killing effect. It can survive and slowly proliferate within macrophages for a long time. When the host's immunity is low, dormant Mycobacterium tuberculosis can be reactivated, leading to the development of active TB. The fact that the pathogen can remain latent in the host or cause persistent infection after infection poses a significant obstacle to the treatment and prevention of the disease. Furthermore, the current challenges in treating TB lie in multidrug-resistant and extensively drug-resistant TB. The lack of new drugs for tuberculosis and insufficient basic research on Mycobacterium tuberculosis are the main reasons for the low cure rate of drug-resistant tuberculosis. Therefore, it is urgent to find new drug targets and develop new anti-tuberculosis drugs to treat tuberculosis.

[0003] According to the World Health Organization's 2022 Global Tuberculosis Report, approximately 10 million new cases of tuberculosis are diagnosed globally each year, and about 1.4 million people die from tuberculosis annually. Currently, tuberculosis diagnosis still faces several technical challenges, mainly including: 1) The slow growth of Mycobacterium tuberculosis and the time-consuming culture process; 2) Insufficient sensitivity and unreliable detection methods; 3) High cost and susceptibility to environmental influences; 4) High diagnostic complexity, making timely and accurate diagnosis difficult.

[0004] Tuberculosis antigen detection methods have been developed for many years, encompassing a variety of approaches, including immunochromatographic strips, enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay, and fluorescence immunoassay (FIA). These methods are all based on detecting tuberculosis antigens in patient fluids or tissues, offering advantages such as speed, accuracy, and sensitivity. However, these methods still have significant limitations. Some kits still exhibit considerable errors in sensitivity and specificity, while others are expensive, require imported equipment and technical cultivation, and have poor clinical applicability. Therefore, tuberculosis antigen detection technology needs further improvement and development, urgently requiring the development of a highly sensitive, specific, user-friendly, and cost-effective method.

[0005] KNCN (kinocilin) ​​protein is a human protein composed of 124 amino acids. It belongs to the myosin superfamily and participates in biological processes such as intracellular transport and cell division. KNCN protein drives intracellular transport by binding to microtubules and engaging in rotational activity. KNCN protein plays a crucial role in nerve cells, particularly in the growth and maintenance of neuronal axons. It transports organelles, RNA, and other important molecules along microtubule tracks, ensuring normal physiological function of nerve cells. Furthermore, KNCN protein participates in the cell cycle and cell division; in mitosis, it is responsible for moving chromosomes from one cell pole to another, ensuring normal chromosome segregation and cell division. Studies have shown that abnormal KNCN protein function is closely related to the occurrence and development of some diseases, such as neurological disorders and cancer. Therefore, regulating KNCN protein activity will have a significant impact on the body and may play an important role in the prevention or treatment of certain diseases. One important pathway for regulating KNCN protein activity is through proteins that can directly interact with KNCN protein. Therefore, proteins that can directly interact with KNCN proteins will have important medicinal value and can be developed into protein or peptide drugs for the prevention or treatment of certain diseases. Summary of the Invention

[0006] This invention utilizes the ability of KNCN protein to simultaneously capture several or more than a dozen tuberculosis antigens in tuberculosis patient specimens. By recombining and purifying KNCN protein, the ability to capture tuberculosis antigens is tested.

[0007] In a first aspect, the present invention provides a KNCN recombinant protein, wherein the KNCN recombinant protein has the ability to capture Mycobacterium tuberculosis antigen, and the amino acid sequence of the KNCN recombinant protein is shown in SEQ ID NO.1.

[0008] SEQ ID NO.1:

[0009] MDIPISSRDFRGLQLACVALGLVAGSIIIGISVSKAAAAMGGVFIGAAVLGLLILAYPFL KARFNLDHILPTIGSLRIHPHPGADHGEGRSSTNGNKEGARSSLSTVSRTLEKLKPGTRGA EEC.

[0010] Secondly, the present invention provides a method for preparing KNCN recombinant protein, the method comprising the following steps:

[0011] S1. Obtain the nucleotide sequence of the KNCN protein, as shown in SEQ ID NO.2.

[0012] S2. Insert the nucleotide sequence obtained in step S1 into a specific vector to construct a recombinant plasmid.

[0013] S3. The recombinant plasmid constructed in step S2 is transfected into the bacterial strain for expression to obtain the recombinant protein of the present invention;

[0014] The KNCN recombinant protein of this invention has the function of capturing tuberculosis antigen.

[0015] SEQ ID NO.2:

[0016] GGATCCATGGACATCCCCATCAGCAGCAGAGACTTCCGCGGCCTGCAGCTGGCCTGCGTGGCTCTCGGGCTGGTGGCTGGCAGCATCATTATCGGCATCTCCGTATCCAAGGCTGCAGCTGCCATGGGCGGTGTCTTTTATTGGCGCTGCTGTTCTGGGGCTCCTCATCTTGGCCTACCCCTTCCTGAAGGCTCG GTTCAACCTGGACCACATCCTGCCTACCATAGGGAGCCTAAGAATCCATCCCCATCCAGGGGCAGACCACGGGGAAGGAAGATCCAGCACCAATGGCAACAAGGAAGGAGCCCGCAGCAGCCTGTCCACCGTGAGCAGGACCCTGGAGAAGCTGAAGCCGGGGACCCGGGGGGCTGAGGAATGCTGAGAATTC.

[0017] Furthermore, the carrier includes, but is not limited to, one or more of pET-28a, pET-30a, pET-22b, pET-24a, and pET-32c, with pET-28a being preferred.

[0018] Furthermore, the strain is selected from E. coli BL21(DE3).

[0019] Thirdly, the present invention provides a kit for detecting Mycobacterium tuberculosis, the kit comprising reagents for detecting Mycobacterium tuberculosis and instructions, wherein the reagents further comprise KNCN recombinant protein, the KNCN recombinant protein having the ability to capture Mycobacterium tuberculosis antigens.

[0020] Fourthly, the present invention provides the use of the KNCN recombinant protein as described in the first aspect in the preparation of a kit for detecting tuberculosis antigen, wherein the KNCN recombinant protein has the ability to capture Mycobacterium tuberculosis antigen.

[0021] Furthermore, the tuberculosis antigen is selected from one or more of Rv0956, Rv1392, Rv1926c, Rv2232, and Rv2892c.

[0022] Beneficial effects:

[0023] KNCN recombinant protein has the ability to specifically and efficiently capture a variety of tuberculosis antigens. The sensitivity and specificity of tuberculosis detection can be improved by using KNCN recombinant protein to efficiently and specifically capture tuberculosis antigens in samples. Detailed Implementation

[0024] The specific embodiments of the present invention will be further described below. It should be noted that these descriptions are for the purpose of aiding understanding the present invention, but do not constitute a limitation thereof. Furthermore, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0025] Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods, and the experimental materials used in the following embodiments are all available through conventional commercial channels.

[0026] Capture: When proteins interact directly, they can bind together relatively firmly, which can also be described as one protein capturing another. The interaction between such proteins mainly relies on the following non-covalent forces: (1) Electrostatic interaction: the interaction between charged amino acid residues. (2) Van der Waals forces: short-range attraction between nonpolar amino acid residues. (3) Hydrophobic interaction: nonpolar residues aggregate in water to form a hydrophobic core, forming hydrophilic-hydrophobic interaction. (4) Hydrogen bond: hydrogen bond interaction between polar residues.

[0027] Recombinant proteins: Recombinant proteins are the ligand proteins that need to be protected. For practical applications, corresponding ligand proteins are required. There are no readily available ligand proteins in nature, so they can only be prepared (by recombinant expression methods to obtain relevant ligand proteins). This is an important part of practical applications.

[0028] Tuberculosis antigen (TB antigen): It can be used as direct evidence of the etiology of tuberculosis for diagnosis and confirmation. After a patient is infected with Mycobacterium tuberculosis, TB antigen will first appear in the body and will remain in the patient's body as the disease progresses. TB antigen detection is not affected by the host's immune function and can be used as direct evidence of the presence of Mycobacterium tuberculosis for diagnosis and confirmation. This avoids false negatives in humoral or cellular immune tests caused by the weak antigenicity of Mycobacterium tuberculosis or the low immune response of tuberculosis patients. The amount of TB antigen in the patient's body can also directly reflect the severity of the disease.

[0029] Example 1: Synthesis of the KNCN protein-coding gene and construction of recombinant plasmids

[0030] The nucleotide sequence of the KNCN protein was obtained and inserted into the vector pET-28a. Subsequent sequencing confirmed the successful construction of the pET-28a-KNCN protein expression plasmid, the sequence of which is shown in SEQ ID NO.2.

[0031] SEQ ID NO.2:

[0032] GGATCCATGGACATCCCCATCAGCAGCAGAGACTTCCGCGGCCTGCAGCTGGCCTGCGTGGCTCTCGGGCTGGTGGCTGGCAGCATCATTATCGGCATCTCCGTATCCAAGGCTGCAGCTGCCATGGGCGGTGTCTTTTATTGGCGCTGCTGTTCTGGGGCTCCTCATCTTGGCCTACCCCTTCCTGAAGGCTCG GTTCAACCTGGACCACATCCTGCCTACCATAGGGAGCCTAAGAATCCATCCCCATCCAGGGGCAGACCACGGGGAAGGAAGATCCAGCACCAATGGCAACAAGGAAGGAGCCCGCAGCAGCCTGTCCACCGTGAGCAGGACCCTGGAGAAGCTGAAGCCGGGGACCCGGGGGGCTGAGGAATGCTGAGAATTC.

[0033] Example 2: Expression and purification of recombinant KNCN protein

[0034] The successfully constructed recombinant plasmid pET-28a-KNCN protein was transfected into E. coli BL21(DE3) to express the recombinant protein. Under IPTG induction, the transformed bacteria successfully expressed the recombinant KNCN protein. After affinity purification using a Ni-NTA-His column, high-purity protein with a relative molecular weight of approximately 15 kDa was obtained, consistent with the expected size. The amino acid sequence of the KNCN recombinant protein is shown in SEQ ID NO.1.

[0035] SEQ ID NO.1:

[0036] MDIPISSRDFRGLQLACVALGLVAGSIIIGISVSKAAAAMGGVFIGAAVLGLLILAYPFL KARFNLDHILPTIGSLRIHPHPGADHGEGRSSTNGNKEGARSSLSTVSRTLEKLKPGTRGA EEC.

[0037] The concentration of KNCN protein was determined to be 1.128 mg / mL using the BCA method. Details are as follows:

[0038] 1) Inoculate E. coli BL21(DE3) strain containing pET-28a-KNCN protein expression plasmid into 5 ml of LB liquid medium containing the corresponding resistance, and culture at 37°C and 200 rpm.

[0039] 2) The next day, the bacterial strain was inoculated into 500 mL of LB liquid medium (kanamycin concentration 50 μg / mL) at a ratio of 1:100 and cultured at 37℃ until OD = 0.4-0.6. IPTG at a concentration of 0.8 mM was added and expression was induced at 25℃ for 12 h. The cells were collected by centrifugation at 12000 rpm and 4℃ for 15 min.

[0040] 3) Centrifuge the induced bacterial culture at 6000 rpm for 10 min, discard the supernatant, and resuspend the precipitate in 200 ml of 500 mM NaCl, 20 mM PBS, and pH 8.0 buffer.

[0041] 4) The resuspended bacteria were sonicated and then centrifuged at 12,000 rpm for 10 min. The supernatant was collected for later use.

[0042] 5) Equilibrate the prepared Ni column (GE) with more than 5 volumes of binding buffer (500mM NaCl, 20mM PBS, pH 8.0) at a flow rate of 1-1.5 ml / min, and adjust the baseline of the UV detector.

[0043] 6) Load the prepared sample at a flow rate of 1 ml / min. Collect the flow through the sample. After loading, wash the absorbance of the UV detector to baseline using a binding buffer (500 mM NaCl, 20 mM PBS, pH 8.0).

[0044] 7) Elute with Washingbuffer (500mM NaCl, 20mM PBS, pH 8.0, 20mM imidazole) and collect the elution peak.

[0045] 8) Elute with elution buffer (500mM NaCl, 20mM PBS, pH 8.0, 60mM imidazole) and collect the elution peak.

[0046] 9) Elute with elution buffer (500mM NaCl, 20mM PBS, pH 8.0, 300mM imidazole) and collect the elution peak.

[0047] 10) The imidazole elution fraction was dialyzed against 20 mM PBS pH 8.0 buffer to obtain purified recombinant protein KNCN. The protein concentration was determined by BCA.

[0048] The amino acid sequence of the recombinant protein KNCN is shown in SEQ ID NO.1.

[0049] SEQ ID NO.1:

[0050] MDIPISSRDFRGLQLACVALGLVAGSIIIGISVSKAAAAMGGVFIGAAVLGLLILAYPFL KARFNLDHILPTIGSLRIHPHPGADHGEGRSSTNGNKEGARSSLSTVSRTLEKLKPGTRGA EEC.

[0051] Example 3: Mass spectrometry identification of tuberculosis antigen captured by KNCN recombinant protein

[0052] Leveraging the ability of KNCN recombinant protein to specifically and efficiently capture multiple tuberculosis antigens, a recombinant protein capture method was constructed to detect tuberculosis antigens in patient samples. The various tuberculosis antigens specifically and efficiently captured by KNCN recombinant protein were identified using mass spectrometry.

[0053] The specific methods for identifying the tuberculosis antigen captured by the KNCN recombinant protein are as follows:

[0054] (1) Coating of KNCN recombinant protein: Dilute the KNCN recombinant protein to 4 μg / ml with coating buffer (0.05 mol / L pH 9.6 carbonate buffer), and add 100 μl of the diluted coating buffer to each well of the microplate. Place the microplate in a humidified chamber and coat overnight at 4°C.

[0055] (2) Wash the plate to remove the liquid from the wells of the microplate. Then fill all the wells with washing buffer (0.15 mol / L pH 7.4 PBS containing 0.05% Tween-20), remove the washing buffer, wrap the plate with absorbent paper to dry, and wash the plate twice.

[0056] (3) Add 250 μl of blocking solution (pH 9.6, 0.05 mol / L carbonate buffer containing 2.0% BSA) to each well of the ELISA plate, place the ELISA plate in a humidified chamber, and incubate at 37°C for 2 h.

[0057] (4) Wash the plate to remove the sealing liquid. Wash twice using the same method as above.

[0058] (5) Add tuberculosis patient samples for incubation. First, add 70 μl of sample diluent to the wells of the ELISA plate, and then add 30 μl of the sample to be tested. When adding the sample, add it to the bottom of the well, trying not to touch the well wall. Incubate at 37°C for 1.5 h.

[0059] (6) Wash the plate to remove the sample solution from the wells of the ELISA plate. Wash 3 times as above.

[0060] (7) Preparation of mass spectrometry identification samples: Add an appropriate amount of mass spectrometry grade trypsin solution to the wells of the ELISA plate and digest overnight at 37°C. After overnight digestion, add FA (formic acid) at a final concentration of 0.1% to terminate digestion.

[0061] (8) Take 10 μL of sample and run it on the instrument. Detect it using liquid chromatography-tandem mass spectrometry (LC-MS / MS, BGI Protein Research Center Co., Ltd.). Use the MASCOT database (http: / / www.matrixscience.com / ) to search and analyze the mass spectrometry data obtained from the detection. The tuberculosis antigens identified are: Rv0956, Rv1392, Rv1926c, Rv2232, and Rv2892c.

[0062] Example 4: Method for detecting Mycobacterium tuberculosis antigen

[0063] Leveraging the specific and efficient capture of multiple tuberculosis antigens by recombinant KNCN protein, a ligand protein capture method was developed for detecting tuberculosis antigens. This involves coating an ELISA plate with recombinant KNCN protein, blocking it, and then eluting. Next, a tuberculosis patient sample is added, incubated, and then eluted. At this point, the KNCN protein captures specific tuberculosis antigens in the sample. Then, tuberculosis antibody (HRP-labeled) is added, incubated, and eluted. Finally, an HRP substrate is added for color development. A positive colorimetric result indicates tuberculosis infection; otherwise, the result is negative. This method is one approach for detecting Mycobacterium tuberculosis infection, but it is not limited to this method. Other methods, such as fluorescent test strips or colloidal gold test strips, can also be used. Specific methods for detecting tuberculosis antigens in samples are as follows:

[0064] 1. Detection reagents for Mycobacterium tuberculosis antigen:

[0065] Antigen coating solution (0.05 mol / L pH 9.6 carbonate buffer), washing buffer (0.15 mol / L pH 7.4 PBS containing 0.05% Tween-20), blocking solution (0.05 mol / L pH 9.6 carbonate buffer containing 2% BSA), dilution buffer (washing buffer containing 0.1% BSA), 1:1000 diluted HRP-labeled rabbit anti-tuberculosis IgG antibody (catalog number ab21189, purchased from Shanghai Unimicron Biotechnology Co., Ltd.), positive serum, negative serum, TMB-H2O2 substrate chromogenic solution [disodium hydrogen phosphate-citrate buffer (pH 5.5) containing TMB (tetramethylbenzidine)], and 2 mol / L sulfuric acid stop solution.

[0066] 2. Detection method for Mycobacterium tuberculosis antigen

[0067] (1) Antigen Coating: Dilute the KNCN recombinant protein to 4 μg / ml with coating buffer, and add 100 μl of the diluted antigen solution to each well of the ELISA plate. Place the ELISA plate in a humidified chamber and coat overnight at 4°C.

[0068] (2) Wash the plate to remove the liquid from the wells of the microplate. Then fill all the wells with washing solution, remove the washing solution, wrap the plate with absorbent paper to dry, and wash the plate twice.

[0069] (3) Add 250 μl of blocking solution (pH 9.6, 0.05 mol / L carbonate buffer containing 2.0% BSA) to each well of the ELISA plate, place the ELISA plate in a humidified chamber, and incubate at 37°C for 2 h.

[0070] (4) Wash the plate to remove the sealing solution, wash twice, and follow the same procedure as above.

[0071] (5) Add sample and incubate: First, add 90 μl of sample diluent to the wells of the ELISA plate, then add 10 μl of the sample to be tested (the final sample dilution is 10-fold). When adding the sample, add it to the bottom of the well, trying not to touch the well wall. Incubate at 37°C for 1.5 h.

[0072] (6) Wash the plate to remove the sample solution from the wells of the ELISA plate. Wash 3 times as above.

[0073] (7) Dilute the enzyme-labeled antibody with antibody dilution buffer (1:1000 dilution). Add 100 μl of the diluted enzyme-labeled antibody to each well, except for the blank wells. Incubate at 37°C in a humidified chamber for 1 h.

[0074] (8) Wash the plate to remove the enzyme-labeled antibody solution. Wash 3 times as above.

[0075] (9) Add 100 μl of color developing solution to each well, gently shake to mix, and develop at room temperature in the dark for 10 to 20 minutes.

[0076] (10) After the color development is completed, add 50 μl of stop solution to each well to stop the reaction (at this time, the blue color will immediately turn yellow).

[0077] (11) Measurement should be performed quickly using an ELISA reader at a wavelength of 450 nm to measure the absorbance (OD value) of each well in the ELISA plate. The measurement should be performed within 20 minutes after adding the stop solution.

[0078] Example 5: Detection of Mycobacterium tuberculosis infection

[0079] The detection reagent for Mycobacterium tuberculosis prepared using the above method was used to detect 110 serum samples from active tuberculosis patients and 37 serum samples from healthy individuals, respectively, according to the above detection method; 102 samples were detected using Mycobacterium tuberculosis nucleic acid (PCR).

[0080] Samples from patients with active tuberculosis were used as a comparison, and the test results are shown in Table 1.

[0081] Table 1. Positive rates of tuberculosis patients detected by different methods

[0082]

[0083] As shown in Table 1, the detection method of the present invention for Mycobacterium tuberculosis antigen has a sensitivity of 69.09% in detecting tuberculosis antigen in the serum of tuberculosis patients, which is significantly higher than the 54.9% of the Mycobacterium tuberculosis nucleic acid (PCR) detection method. The specificity of this detection method is 91.9% (1-8.11%=91.9%).

Claims

1. A kit for detecting Mycobacterium tuberculosis, characterized in that, The kit contains reagents for detecting Mycobacterium tuberculosis and instructions. The reagents further contain a KNCN recombinant protein, which has the ability to capture Mycobacterium tuberculosis antigens. The tuberculosis antigens captured by the KNCN recombinant protein can be identified by mass spectrometry. The amino acid sequence of the KNCN recombinant protein is shown in SEQ ID NO.1: MDIPIISSRDFRGLQLACVALGLVAG SIIIGISVSKAAAAMGGVFIGAAVLGLLILAYPFLKARFNLDHILPTIGSLRIHPHPGADHGEGRSSTNGNKEGARSSLSTVSRTLEKLKPGTRGAEEC.

2. The use of a recombinant KNCN protein in the preparation of a kit for detecting tuberculosis antigen, characterized in that, The KNCN recombinant protein has the ability to capture Mycobacterium tuberculosis antigen; the amino acid sequence of the KNCN recombinant protein is shown in SEQ ID NO.1: MDIPIISSRDFRGLQLACVALGLVAGSIIIGISVSKAAAAMGGVFIGAAVLGL LILAYPFLKARFNLDHILPTIGSLRIHPHPGADHGEGRSSTNGNKEGARSSLSTVSRTLEKLKPGTRGAEEC.

3. The use of the KNCN recombinant protein as described in claim 2 in the preparation of a kit for detecting tuberculosis antigen, characterized in that, The tuberculosis antigen is selected from one or more of Rv0956, Rv1392, Rv1926c, Rv2232, and Rv2892c.